



SEP 17 2001

5145 '01 031 10 47:54

Mr. Michael A. Pelton
Vice President
Biotech Corporation
107 Oakwood Drive
Glastonbury, Connecticut 06033

Dear Mr. Elton:

This is in response to your letter of July 10, 2001 to the Food and Drug Administration (FDA) pursuant to 21 U.S.C. 343(r)(6) (section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the Act)). Your submission states that Biotech Corporation is making the following claims, among others, for the product **VenaFit™**:

“(to) help improve leg vein circulation and...its associated discomfort”
“Minimize varicose...veins...”

We also are aware that the product label for this product includes the following claim that is subject to the notification requirement in the Act that you did not include in your submission:

“...help improve leg vein circulation as well as protect against swelling, and its associated discomfort.”

21 U.S.C. 343(r)(6) makes clear that a statement included in labeling under the authority of that section may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases. The statements that you are making for this product suggest that it is intended to treat, prevent, cure, or mitigate diseases, namely disorders of venous circulation, including varicose veins. These claims do not meet the requirements of 21 U.S.C. 343(r)(6). These claims suggest that this product is intended for use as a drug within the meaning of 21 U.S.C. 321(g)(1)(B), and that it is subject to regulation under the drug provisions of the Act. If you intend to make claims of this nature, you should contact FDA's Center for Drug Evaluation and Research (CDER), Office of Compliance, HFD-310, 7520 Standish Place, Rockville, Maryland 20855.


975-0163

LET 544

Page 2 - Mr. Michael A. Elton

Please contact us if we may be of further assistance.

Sincerely,

A handwritten signature in black ink, appearing to read "John B. Foret". The signature is fluid and cursive, with a long horizontal flourish extending to the right.

John B. Foret

Director

Division of Compliance and Enforcement

Office of Nutritional Products, Labeling
and Dietary Supplements

Center for Food Safety


and Applied Nutrition

Copies:

FDA, Center for Drug Evaluation and Research, Office of Compliance, HFD-300

FDA, Office of the Associate Commissioner for Regulatory Affairs, Office of
Enforcement, HFC-200

FDA, New England District Office, Office of Compliance, HFR-NE240



July 10, 2001

Office of Special Nutritionals (HFS-450)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 C St. SW
Washington DC 20204

Re: Notification of DSHEA nutritional support claim for Biotech Corporation, Inc., VenaFit Dietary Supplement

Dear Sir or Madam:

The purpose of this letter is to provide notification pursuant to section 403 (r)(6) of the Federal Food, Drug, and Cosmetic Act ("the Act") and 7 C.F.R. § 101.93 that Biotech Corporation, Inc., is marketing a dietary supplement that bears a statement of nutritional support as defined in section 403 (r)(6) of the Act.

The labeling for VenaFit bears the following statements:

"Healthy leg formula"

"promotes proper leg circulation and health"

"natural leg health supplement"

"(to) help improve leg vein circulation and . . . its associated discomfort"

"minimize varicose/spider veins and increase venous efficiency for optimal vein health"

"promotes health"

Biotech Corporation, Inc. has on file substantiation that the above statements are truthful and not misleading. To the best of my knowledge, the information contained in this notice is complete and accurate.

Sincerely,

Michael A. Pelton
Vice President

107 OAKWOOD DRIVE
GLASTONBURY
CONNECTICUT
0 6 0 3 3

PHONE 860 633 8111
888 SHEN MIN
FAX 860 682 6863

77259

The Nutraceutical Product Leader

